澳大利亚亚裔癫痫患者HLA-B*15:02基因分型的经济学评价
该研究采用决策分析和马尔可夫模型模拟澳大利亚亚裔新诊断癫痫患者接受卡马西平治疗前进行HLA-B*15:02基因分型的成本效果。
要点
- 筛查策略在88.60%的模拟中被优选,敏感性分析支持结果稳健。
- 筛查虽减少生命年,但通过避免严重皮肤不良反应改善质量调整生命年。
核心结论
- 对考虑卡马西平治疗的澳大利亚亚裔癫痫患者,HLA-B*15:02筛查是具有成本效果的策略。
研究设计与样本
- 采用决策分析和马尔可夫模型模拟成人亚裔澳大利亚新诊断癫痫患者的临床轨迹。
- 从澳大利亚医疗保健部门视角进行终身时间 horizon 的成本效果和成本效用分析。
- 研究于2023年5月进行,数据分析于2023年8月至11月完成。
主要发现
- 筛查组人均额外成本为114澳元(95%CI,-83至374;76美元;95%CI,-55至248)。
- 筛查组减少0.0152生命年(95%CI,0.0045至0.0287),但增加0.00722 QALYs(95%CI,-0.0247至-0.01210)。
关键数值与推荐
- 敏感性分析显示,筛查在不同成本、效用值、转移概率和支付阈值下均保持成本效果。
临床怎么用
- 对于澳大利亚亚裔癫痫患者,在启动卡马西平治疗前可考虑进行HLA-B*15:02基因分型以指导用药选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The HLA-B*15:02 allele has been associated with an increased risk of carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in specific Asian populations (including Han Chinese, Malaysian, Thai, and Vietnamese individuals). While HLA-B*15:02 genotype testing in Asian populations is recommended by several international prescribing guidelines, it is not subsidized by the Medicare Benefits Schedule in Australia. OBJECTIVE: To evaluate the cost-effectiveness of HLA-B*15:02 genotyping in Asian Australian patients with epilepsy. DESIGN, SETTING, AND PARTICIPANTS: A model with components of decision analysis and Markov simulation was developed to simulate clinical trajectories of adult Asian Australian patients with newly diagnosed epilepsy being considered for carbamazepine treatment. Cost-effectiveness and cost-utility analyses over a lifetime time horizon were conducted from the perspective of the Australian health care sector. The study was conducted in May 2023 and data analysis was performed from August 2023 to November 2023. INTERVENTION: No HLA-B*15:02 genotyping and the empirical initiation of treatment with carbamazepine vs HLA-B*15:02 genotyping and the initiation of treatment with valproate in allele carriers. MAIN OUTCOMES AND MEASURES: Life-years (LYs), quality-adjusted life-years (QALYs), and costs in 2023 Australian dollars (A$); incremental cost-effectiveness ratios. RESULTS: HLA-B*15:02 screening was associated with an additional mean cost of A$114 (95% CI, -A$83 to A$374; US$76; 95% CI, -US$55 to US$248) and a reduction in 0.0152 LYs (95% CI, 0.0045 to 0.0287 LYs) but improvement by 0.00722 QALYs (95% CI, -0.0247 to -0.01210) compared with no screening, resulting in an incremental cost-effectiveness ratio of A$15 839 per QALY gained (US$10 523 per QALY). Therefore, universal genotyping for Asian Australian individuals was cost-effective compared with current standards of practice at the A$50 000 per QALY willingness-to-pay threshold. Sensitivity analyses demonstrated that the intervention remained cost-effective across a range of costs, utilities, transition probabilities, and willingness-to-pay thresholds. At the A$50 000 per QALY willingness-to-pay threshold, universal screening was the preferred strategy in 88.60% of simulations. CONCLUSIONS AND RELEVANCE: The results of this economic evaluation suggest that HLA-B*15:02 screening represents a cost-effective choice for Asian Australian patients with epilepsy who are being considered for treatment with carbamazepine.
引用
- Gu Y, Shih STF, Geevasinga N, et al. Economic Evaluation of HLA-B*15:02 Genotyping for Asian Australian Patients With Epilepsy. JAMA Dermatol. 2024. PMID: 38717780. doi:10.1001/jamadermatol.2024.1037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。